Stock Research for ACRX


Featured Broker: Ally Invest

Get the due diligence for another stock.


ACRX Stock Chart & Research Data

The ACRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ACRX Due diligence Resources & Stock Charts

The ACRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACRX Detailed Price Forecast - CNN Money CNN View ACRX Detailed Summary - Google Finance
Yahoo View ACRX Detailed Summary - Yahoo! Finance Zacks View ACRX Stock Research & Analysis -

Stock Analysis

TradeIdeas View ACRX Trends & Analysis - Trade-Ideas Barrons View ACRX Major Holders - Barrons
NASDAQ View ACRX Call Transcripts - NASDAQ Seeking View ACRX Breaking News & Analysis - Seeking Alpha
Spotlight View ACRX Annual Report - OTC Report View ACRX OTC Short Report -
TradeKing View ACRX Fundamentals - TradeKing Charts View ACRX SEC Filings - Bar Chart
WSJ View Historical Prices for ACRX - The WSJ Morningstar View Performance/Total Return for ACRX - Morningstar
MarketWatch View the Analyst Estimates for ACRX - MarketWatch CNBC View the Earnings History for ACRX - CNBC
StockMarketWatch View the ACRX Earnings - StockMarketWatch MacroAxis View ACRX Buy or Sell Recommendations - MacroAxis
Bullish View the ACRX Bullish Patterns - American Bulls Short Pains View ACRX Short Pain Metrics -

Social Media Mentions

StockTwits View ACRX Stock Mentions - StockTwits PennyStocks View ACRX Stock Mentions - PennyStockTweets
Twitter View ACRX Stock Mentions - Twitter Invest Hub View ACRX Investment Forum News - Investor Hub
Yahoo View ACRX Stock Mentions - Yahoo! Message Board Seeking Alpha View ACRX Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ACRX - Insider Cow View Insider Transactions for ACRX - Insider Cow
CNBC View ACRX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACRX - OTC Markets
Yahoo View Insider Transactions for ACRX - Yahoo! Finance NASDAQ View Institutional Holdings for ACRX - NASDAQ

Stock Charts

FinViz View ACRX Stock Insight & Charts - StockCharts View ACRX Investment Charts -
BarChart View ACRX Stock Overview & Charts - BarChart Trading View View ACRX User Generated Charts - Trading View

Latest Financial News for ACRX

AcelRX Shares Should More Than Double On Painkiller Assets, Landenburg Says In Bullish Initiation
Posted on Thursday August 16, 2018

The company's lead candidate Dsuvia, a 30mcg sufentanil NanoTab placed sublingually by a health care professional via a single-dose applicator, is being touted as a substitute for intravenous opioids, currently the gold standard to treat moderate-to-severe pain in emergency departments, Higgins said in a Thursday note.

Edited Transcript of ACRX earnings conference call or presentation 2-Aug-18 8:30pm GMT
Posted on Tuesday August 14, 2018

Q2 2018 AcelRx Pharmaceuticals Inc Earnings Call

Is AcelRx Pharmaceuticals (ACRX) Outperforming Other Medical Stocks This Year?
Posted on Thursday August 09, 2018

Is (ACRX) Outperforming Other Medical Stocks This Year?

AcelRx Pharmaceuticals Announces Full Exercise of Underwriters' Option to Purchase Additional Shares
Posted on Wednesday August 08, 2018

REDWOOD CITY, Calif., Aug. 8, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (ACRX) (AcelRx), a specialty pharmaceutical company focused on innovative therapies for use in medically supervised settings, today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,090,909 shares of AcelRx's common stock. Including this option exercise, total gross proceeds to AcelRx from the offering of an aggregate 8,363,636 shares at a price to the public of $2.75 per share were approximately $23.0 million, before deducting the underwriting discounts and commissions and other offering expenses payable by AcelRx. Ladenburg Thalmann acted as co-manager for the offering.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.